Logo image of GOSS

GOSSAMER BIO INC (GOSS) Stock Fundamental Analysis

NASDAQ:GOSS - Nasdaq - US38341P1021 - Common Stock - Currency: USD

1.18  +0.09 (+8.26%)

Premarket: 1.18 0 (0%)

Fundamental Rating

2

GOSS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. GOSS may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, GOSS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GOSS had negative earnings in the past year.
GOSS had a negative operating cash flow in the past year.
In the past 5 years GOSS always reported negative net income.
In the past 5 years GOSS always reported negative operating cash flow.
GOSS Yearly Net Income VS EBIT VS OCF VS FCFGOSS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -17.93%, GOSS is in the better half of the industry, outperforming 78.97% of the companies in the same industry.
The Return On Equity of GOSS (-191.67%) is worse than 67.74% of its industry peers.
Industry RankSector Rank
ROA -17.93%
ROE -191.67%
ROIC N/A
ROA(3y)-53.25%
ROA(5y)-54.59%
ROE(3y)-791.28%
ROE(5y)-528.46%
ROIC(3y)N/A
ROIC(5y)N/A
GOSS Yearly ROA, ROE, ROICGOSS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 0 0 0 0 0 0 0 0 0 0

1.3 Margins

GOSS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GOSS Yearly Profit, Operating, Gross MarginsGOSS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

More info and screens

3

2. Health

2.1 Basic Checks

GOSS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GOSS has more shares outstanding
GOSS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for GOSS has been reduced compared to a year ago.
GOSS Yearly Shares OutstandingGOSS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
GOSS Yearly Total Debt VS Total AssetsGOSS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -4.33, we must say that GOSS is in the distress zone and has some risk of bankruptcy.
GOSS has a Altman-Z score (-4.33) which is comparable to the rest of the industry.
GOSS has a Debt/Equity ratio of 6.70. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of GOSS (6.70) is worse than 84.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 6.7
Debt/FCF N/A
Altman-Z -4.33
ROIC/WACCN/A
WACC9.26%
GOSS Yearly LT Debt VS Equity VS FCFGOSS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

GOSS has a Current Ratio of 6.88. This indicates that GOSS is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.88, GOSS is doing good in the industry, outperforming 67.91% of the companies in the same industry.
GOSS has a Quick Ratio of 6.88. This indicates that GOSS is financially healthy and has no problem in meeting its short term obligations.
GOSS has a better Quick ratio (6.88) than 68.09% of its industry peers.
Industry RankSector Rank
Current Ratio 6.88
Quick Ratio 6.88
GOSS Yearly Current Assets VS Current LiabilitesGOSS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

GOSS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.30%, which is quite impressive.
EPS 1Y (TTM)78.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 26.40% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 25.82% on average over the next years. This is a very strong growth
EPS Next Y-161.1%
EPS Next 2Y-28.21%
EPS Next 3Y10.73%
EPS Next 5Y26.4%
Revenue Next Year-81.67%
Revenue Next 2Y-27.04%
Revenue Next 3Y2.96%
Revenue Next 5Y25.82%

3.3 Evolution

GOSS Yearly Revenue VS EstimatesGOSS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
GOSS Yearly EPS VS EstimatesGOSS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GOSS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GOSS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GOSS Price Earnings VS Forward Price EarningsGOSS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GOSS Per share dataGOSS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.21%
EPS Next 3Y10.73%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GOSS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GOSSAMER BIO INC

NASDAQ:GOSS (5/20/2025, 8:00:23 PM)

Premarket: 1.18 0 (0%)

1.18

+0.09 (+8.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners76.64%
Inst Owner Change-11.6%
Ins Owners0.69%
Ins Owner Change0%
Market Cap268.12M
Analysts82.67
Price Target6.33 (436.44%)
Short Float %4.58%
Short Ratio6.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.31%
Min EPS beat(2)7.13%
Max EPS beat(2)13.49%
EPS beat(4)3
Avg EPS beat(4)4.08%
Min EPS beat(4)-5.81%
Max EPS beat(4)13.49%
EPS beat(8)7
Avg EPS beat(8)6.28%
EPS beat(12)9
Avg EPS beat(12)4.68%
EPS beat(16)11
Avg EPS beat(16)3.34%
Revenue beat(2)2
Avg Revenue beat(2)27.62%
Min Revenue beat(2)20.7%
Max Revenue beat(2)34.54%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.61%
PT rev (3m)-13.87%
EPS NQ rev (1m)-0.19%
EPS NQ rev (3m)1.06%
EPS NY rev (1m)4.41%
EPS NY rev (3m)6.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)14.27%
Revenue NY rev (1m)-5.35%
Revenue NY rev (3m)-2.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.34
P/FCF N/A
P/OCF N/A
P/B 9.09
P/tB 9.09
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.5
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.93%
ROE -191.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.25%
ROA(5y)-54.59%
ROE(3y)-791.28%
ROE(5y)-528.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 6.7
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.88
Quick Ratio 6.88
Altman-Z -4.33
F-Score6
WACC9.26%
ROIC/WACCN/A
Cap/Depr(3y)7.47%
Cap/Depr(5y)43.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.79%
EPS Next Y-161.1%
EPS Next 2Y-28.21%
EPS Next 3Y10.73%
EPS Next 5Y26.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-81.67%
Revenue Next 2Y-27.04%
Revenue Next 3Y2.96%
Revenue Next 5Y25.82%
EBIT growth 1Y65.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-149.74%
EBIT Next 3Y33.89%
EBIT Next 5Y34.99%
FCF growth 1Y97.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y97.82%
OCF growth 3YN/A
OCF growth 5YN/A